HIV, lenacapavir

Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,
Dr. Maya Green reveals 3 HIV prevention strategies
Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on Black communities in an enlightening Health IQ interview.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
The Washington Informer1h
Empowering Women and Girls: Advancing HIV Prevention
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Study highlights gaps in HPV-related cancer prevention for people living with HIV
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Becker's Hospital Review1h
HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
The Financial Express6h
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Rolling Out13d
HIV breakthrough faces critical funding cuts
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
Our progress in ending the HIV/AIDS epidemic shows the importance of federal support
We can now prevent HIV transmissions and deaths — progress impossible without investments from the U.S. government ...
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...
News Medical on MSN6h
Gaps in HPV cancer screening and prevention identified for people living with HIV
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.